DELBIOS
PHARMACEUTICALS

Extended Request for Quotation (RFQ) – 2-week Dose Range Finding (DRF) study and 4 Week Toxicity Study with 2 Week Recovery Period with Analytical (GLP) in minipig

Reference Code: RFQ-TOX-006-2025

Date of Issue: 29/12/2025

Deadline for Submission: 16/01/2026

Contact Person: Nora Ventosa

Email: info@delbios.com

1. Background

Delbios Pharmaceuticals SL is developing a nanomedicine for the treatment of rare diseases under an EIC Transition project (Nano4Rare, n°101136772). The nanomedicine, called nanoGLA is a novel recombinant human GLA produced in Chinese Hamster Ovary (CHO) cell culture and integrated into nanoliposomes. This new delivery system is supposed to increase the plasma elimination half-life and tissue distribution, efficacy, and reduce the immunogenicity compared to the current standard of care. NanoGLA is administered by the intravenous route.

NanoGLA is composed of DPPC phospholipid, cholesterol, and cholesterol-Polyethylene Glycol (PEG)400-RGD targeting ligand, with a small amount of the quaternary ammonium surfactant MKC (Myristalkonium chloride).



As part of the preclinical development plan of the nanoGLA, we require the performance of the toxicological program in second specie, including two main studies:

- 2-week Dose Range Finding (DRF) study in minipig
- 4-Week Toxicity Study with 2 Week Recovery Period in minipig (GLP)

This RFQ is issued to select the most suitable service provider for determination of Dose Range Finding (DRF) and 4-week toxicity study (GLP) of nanoGLA in minipig.

2. Scope of Work

NanoGLA is a drug candidate in which human α-galactosidase A (GLA) is encapsulated within liposomal nanovesicles. These nanovesicles are expected to protect the enzyme, enhance its stability and biodistribution, facilitate its transport throughout the body, and improve delivery to target tissues, including the central nervous system (CNS). In addition, the nanovesicles may reduce toxicity and immune responses against the enzyme. This drug candidate is being developed as an enzyme replacement therapy for Fabry disease.

The **2-week Dose Range Finding (DRF) study** and the **4-week toxicity study with a 2-week recovery period (GLP),** including analytical support, in minipigs are essential components of preclinical drug development to ensure safety, dose selection, and regulatory compliance before initiating clinical trials. These studies correspond to *WP1*, *Task 1.4 General Toxicology Studies* from the Nano4Rare project. Additionally, **cardiovascular endpoints** that corresponds to *Task 1.5 Safety Pharmacology* (i.e. Cardiovascular system: blood pressure, heart rate andelectrocardiogram in non-rodent) are included in the GLP toxicology study.

2-week Dose Range Finding (DRF) study

This study is conducted to:

- Identify dose levels that are well tolerated and those that may cause toxicity
- Support the selection of appropriate doses for longer-term toxicity studies, such as the 4- week toxicity study (GLP).
- Provide early information on target organs of toxicity and dose-response relationships.
- Include toxicokinetics (TK); samples may be collected at 1 min, 10 min, 30 min, 1 h, 2 h 4 h, 8 h and 24 h on Day 1 and Day 15 post dosing; 2 animals/sex/group.

The experimental design that we propose is as follows, referring to group assignment and dose level:

Group	Subgroup	Article	Dose Level	Dose Concentration	Dosing Regimen	No. of Animals	
						Males	Females
1 (UN - high)	1 (Tox)	Unloaded Nanoliposomes	High	TBD	Days 1, 4, 8, 11 and 15	2	2
2 (Nano-GLA - Low)	1 (Tox)	NanoGLA	Low	TBD		2	2
3 (Nano-GLA - Low)	1 (Tox)	NanoGLA	Medium	TBD		2	2
4 (Nano-GLA - High)	1 (Tox)	NanoGLA	High	TBD		2	2

4-week toxicity study with 2-week recovery period (GLP)

This pivotal GLP-compliant study is required to:

- Assess the systemic toxicity of the compound following repeated dosing.
- Identify potential target organs, severity, and reversibility of toxic effects.
- Evaluate whether observed toxicities resolve or persist after cessation of dosing (recovery period).
- Support the determination of the NOAEL (No Observed Adverse Effect Level), which is critical for setting safe starting doses in humans.
- Include regulatory TK on first (Day 1) and last day of dosing (Day 29) from all animals (including recovery animals)
- Safety Pharmacology: Cardiovascular system: blood pressure, heart rate and electrocardiogram in non-rodent (cardiovascular endpoints included in the GLP toxicology study)

The experimental design that we propose is as follows:

Group	Subgroup	Article	Dose Level	Dose Concentration	Dosing Regimen*	No. of Animals	
						Males	Females
1 (Control)	1 (Tox)	Vehicle control	TBD	TBD	1×/week	3 + 2 for recovery	3 + 2 for recovery
2 (UN - high)	1 (Tox)	Unloaded Nanoliposomes	High	TBD	1×/week	3 + 2 for recovery	3 + 2 for recovery
3 (Nano-GLA - Low)	1 (Tox)	nanoGLA	Low	TBD	1×/week	3	3
3 (Nano-GLA - Medium)	1 (Tox)	nanoGLA	Medium	TBD	1×/week	3	3
4 (Nano-GLA - High)	1 (Tox)	nanoGLA	High	TBD	1×/week	3 + 2 for recovery	3 + 2 for recovery

* The frequency of dosing shall be based on the results of the DRF study

3. Service Requirements (SRD06)

- Minimum 3 years' experience in toxicological studies in minipig or similar species.
- Experience with nanoformulations preclinical development or biologicals is an advantage
- Audit readiness (including EU Commission or EIC bodies)
- Acceptance of confidentiality, ethics, and funding visibility clauses
- Retention of records for 5 years after project end
- Provision of interim reports. If part of payment is on contract signature
- The final report shall be delivered no later than 4 weeks following the completion of the study.
- Payments shall be milestone-based and conditional upon the delivery and acceptance of agreed project deliverables. Initial payments may be linked to the submission of an appropriate documented deliverable.

4. Submission Instructions

All proposals must include:

1. Technical proposal and study plan
2. Full cost breakdown
3. Timeline for study start and final report
4. Payment terms

If the proposal is selected, Delbios Pharmaceuticals will also need:

5. Signed declaration of no conflict of interest
6. Acceptance of audit rights and confidentiality terms

5. Evaluation Criteria

Main Criterion	Weight	Subcriterion	Sub-weight	Evaluation Indicators
Scientific & Technical Proposal	30%	Quality, clarity, and completeness of methodology	20%	Proposal clearly describes experimental steps, objectives, expected outcomes, and deliverables.
		Risk assessment and mitigation strategies	10%	Identification of potential risks and feasibility of proposed mitigation plans.
Relevant Experience	20%	Experience with nanomedicines, biologics, or enzyme replacement therapies	10%	Relevant projects or publications demonstrating technical expertise.
		Experience in EU-funded projects or with regulatory bodies	10%	Demonstrated capacity to meet EU project requirements and regulatory interactions.
Timeline	20%	Realism and feasibility of proposed schedule	10%	Schedule aligns with project milestones and deliverables.
		Capacity to meet 2-month validation window and 4-	10%	Demonstrated ability to meet tight deadlines.

		week reporting deadline		
Cost Competitiveness	30%	Price / total cost	15%	The final proposed cost, which will be an important factor in the evaluation.
		Justification of costs in relation to scope and quality	10%	Costs must be reasonable and proportional to the proposed work and quality.
		Payment terms aligned with project needs	5%	Payment schedule must be aligned with project cash flow requirements.

Scoring Notes:

- Each subcriterion is scored 0–5 (0 = unacceptable, 5 = excellent).
- Weighted scores are calculated by multiplying sub-weight by the score.
- Total score = sum of all weighted sub-scores.
- **Technical criteria minimum threshold:** Scientific & Technical Proposal and Timeline must score at least 3/5 for a proposal to be considered in the cost evaluation.

6. Confidentiality

All RFQ contents and submitted proposals will be treated confidentially. Sensitive or proprietary information must be marked clearly by the applicants.

7. Submission Deadline

All quotations must be submitted by 16/01/2026 to: info@delbios.com

Subject: RFQ-TOX-006-2025

8. Legal and Funding Clauses

- A contract will be signed including obligations on confidentiality, audit rights, EU funding visibility, and ethics compliance.
- The European Commission, OLAF, EIC and the European Court of Auditors must be granted full audit rights.
- Costs must comply with the Horizon Europe eligibility rules.
- Subcontractor must retain all records for at least 5 years after the project ends.

9. Disclaimer

Delbios reserves the right to cancel or modify this RFQ, and is not obliged to award any subcontract as a result of this process.